Skip to main content

Table 2 Characteristics of patients with BCORMUT or BCORWT received decitabine therapy

From: Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Characteristics BCORWT (n = 181) BCORMUT (n = 14) p value
Age, median (range), year 62 (17–85) 62 (23–80) 0.558
Gender, male:female, n (%) 120:61 (66:34) 7:7 (50:50) 0.250
WHO/FAB classification, n (%)    0.891
 RCMD 47 (26.0) 3 (21.4)  
 RAEB-1 57 (31.5) 3 (21.4)  
 RAEB-2 39 (21.5) 5 (35.7)  
 RAEB-t 12 (6.6) 1 (7.1)  
 CMML-1 17 (9.4) 1 (7.1)  
 CMML-2 9 (5.0) 1 (7.1)  
IPSS risk, n (%)    0.858
 Intermediate-1 84 (46.4) 7 (50.0)  
 Intermediate-2 77 (42.5) 5 (35.7)  
 High 20 (11.1) 2 (14.3)  
Cytogenetic risk group, n (%)    
 Good 108 (59.7) 12 (85.7) 0.072
 Intermediate 31 (17.1) 2 (14.3)  
 Poor 42 (23.2) 0  
Decitabine cycles, median (range), n 4 (1–11) 4 (2–7) 0.411